Osteoarthritis, HipNCT05829733
6-month Efficacy and Safety of Synolis VA 80/160 in Hip Osteoarthritis
A study testing SYNOLIS VA 80/160 in people with Osteoarthritis, Hip, run by Aptissen SA at 3 sites in France.
Trial summary
Multicenter, independent study of Synolis VA 80/160 over a period of 6 months Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Osteoarthritis, Hip
- What is being tested?
- SYNOLIS VA 80/160
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 3 sitesFrance
- Study dates
- 27 May 2024to Apr 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient over 18 years of age,
- Patient with osteoarthritis of the hip. The diagnosis is based on the following criteria:
- Treated hip pain: Oxford score ≥ 21/60,
- Kellgren-Lawrence positive X-ray stage: II - III (inclusion radiograph dated no more than 6 months before the inclusion visit),
- Symptoms related to osteoarthritis of the hip for at least 2 months,
- Failure of treatments (i.e., inadequate or ineffective response to analgesics and/or NSAIDs or intolerance to NSAIDs or low-grade opioids (leaving an OXFORD score ≥ 21/60),
- Informed consent form signed by the patient,
- The patient has never had a visco supplement injection or corticosteroid injection in the hip to be treated (or more than 6 months old).
Who cannot join
- Pregnancy,
- Participation in another clinical trial,
- Skin lesion near the injection site,
- Recent or old infection of the affected joint,
- Patient with a programmed arthroplasty,
- Patient with a pathology that makes decision-making impossible,
- The patient must not have undergone non-prosthetic hip-conserving surgery such as osteotomy or arthroscopy less than 12 months old.
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
France3 sites, 3 recruiting
- Recruiting
Service de Rhumatologie, Hôpital Nord Franche-Comté
Belfort
Thierry Conrozier, Dr
- Recruiting
Service de chirurgie orthopédique et traumatologie Centre Hospitalier de Dunkerque CHD
Dunkirk
Nicolas Jan, Dr
- Recruiting
Service d'Orthopédie II (Membre Inférieur, Chirurgie du Sport et Chirurgie Septique) Hôpital Salengro, CHRU de Lille
Lille
Henri Migaud, Pr
About this study
Official title: 6-month Evaluation of the Efficacy and Safety of Synolis VA 80/160 in the Treatment of Symptomatic Hip Osteoarthritis
Multicenter, independent study of Synolis VA 80/160 over a period of 6 months
- Conditions
- Osteoarthritis, Hip
- Being tested
- SYNOLIS VA 80/160
- Keywords
- Osteoarthritis, Hip osteoarthritis, Hyaluronic acid
- Medical subject headings
- Osteoarthritis, Hip, Osteoarthritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SYNOLIS VA 80/160Device
SYNOLIS VA 80/160 (hyaluronic acid 80 mg, sorbitol 160 mg)
| Study group | Role | What they receive |
|---|---|---|
| SYNOLIS VA 80/160 | Experimental | Single guided intra-articular injection of SYNOLIS VA 80/160 Receives: Device: SYNOLIS VA 80/160 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evolution of the Oxford Hip Score (OXFORD 12)
Oxford Hip Score (OXFORD 12) composed of 12 questions measuring pain and hip function. Question includes 5 possible answers corresponding to a value from 1 to 5, with 5 representing the highest level of severity, and 1, the total or almost total absence of symptoms.
Measured: 6 months (M6)
Secondary outcomes (4)
Evolution of the Oxford Hip Score (OXFORD 12)
Oxford Hip Score (OXFORD 12) composed of 12 questions measuring pain and hip function. Question includes 5 possible answers corresponding to a value from 1 to 5, with 5 representing the highest level of severity, and 1, the total or almost total absence of symptoms.
Measured: Month 3, Month 3 to Month 6
Self-assessment symptoms evolution
7-point Likert scale (-3 to +3)
Measured: Month 3, Month 3 to Month 6
MCID Oxford Hip Score (OXFORD 12)
Minimum clinically important difference on the Oxford Hip Score (OXFORD 12)
Measured: Month 3, Month 3 to Month 6
Hip prosthesis placement after the injection
Number of Participants with Hip prosthesis placement
Measured: Month 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Apr 2023
- Study start27 May 2024
- Primary completionApr 2027 (estimated)
- Study completionApr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Osteoarthritis, HipStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Aptissen SA
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05829733
- Sponsor's protocol ID
- PMCF A-SYN400 Hip
- Status last verified
- Dec 2025
- First submitted
- 20 Mar 2023
- Last updated
- 12 Dec 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- 6-month Evaluation of the Efficacy and Safety of Synolis VA 80/160 in the Treatment of Symptomatic Hip Osteoarthritis
- ClinicalTrials.gov ID
- NCT05829733
- Acronym / sponsor ID
- PMCF A-SYN400 Hip
- Conditions
- Osteoarthritis, Hip
- Keywords
- Osteoarthritis, Hip osteoarthritis, Hyaluronic acid
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- Aptissen SAIndustry (pharma, biotech, devices)
- Study start
- 27 May 2024 (actual)
- Primary completion
- Apr 2027 (estimated)
- Study completion
- Apr 2027 (estimated)
- First posted
- 26 Apr 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Multicenter, independent study of Synolis VA 80/160 over a period of 6 months
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| SYNOLIS VA 80/160 | Experimental | Device: SYNOLIS VA 80/160Single guided intra-articular injection of SYNOLIS VA 80/160 |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Patient over 18 years of age,
- Patient with osteoarthritis of the hip. The diagnosis is based on the following criteria:
- Treated hip pain: Oxford score ≥ 21/60,
- Kellgren-Lawrence positive X-ray stage: II - III (inclusion radiograph dated no more than 6 months before the inclusion visit),
- Symptoms related to osteoarthritis of the hip for at least 2 months,
Key exclusion criteria (7 listed)
- Pregnancy,
- Participation in another clinical trial,
- Skin lesion near the injection site,
- Recent or old infection of the affected joint,
- Patient with a programmed arthroplasty,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SYNOLIS VA 80/160SYNOLIS VA 80/160 (hyaluronic acid 80 mg, sorbitol 160 mg) | Device | SYNOLIS VA 80/160 |
Primary outcome
Evolution of the Oxford Hip Score (OXFORD 12)
Time frame: 6 months (M6)
Oxford Hip Score (OXFORD 12) composed of 12 questions measuring pain and hip function. Question includes 5 possible answers corresponding to a value from 1 to 5, with 5 representing the highest level of severity, and 1, the total or almost total absence of symptoms.
4 secondary outcomes
Evolution of the Oxford Hip Score (OXFORD 12)
Time frame: Month 3, Month 3 to Month 6
Self-assessment symptoms evolution
Time frame: Month 3, Month 3 to Month 6
MCID Oxford Hip Score (OXFORD 12)
Time frame: Month 3, Month 3 to Month 6
Hip prosthesis placement after the injection
Time frame: Month 6
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Dec 2025.
Related trials for Osteoarthritis, Hip
Active, not recruiting
Effectiveness of Therapeutic Exercises on Spinopelvic Mobility
Osteoarthritis (OA) of the Hip
Recruiting
Intravenous Dexamethasone (0 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in Total Hip Arthroplasty
Osteoarthritis, Hip, Hip Osteoarthritis
Recruiting
Effects of EDUcation and EXercise Compared to Education Alone on Clinical and Physiological Outcomes in Patients With Hip Osteoarthritis
Hip Osteoarthritis
Recruiting
Comparison of Spinal Anesthesia With Intrathecal Morphine Versus PENG Block With or Without Dexamethasone in Hip Arthroplasty
Arthropathy of Hip, Hip Osteoarthritis
RecruitingPhase 4
PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty
Hip Osteoarthritis, Hip Arthropathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing SYNOLIS VA 80/160 in people with Osteoarthritis, Hip, run by Aptissen SA at 3 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Eduard Vidovic, MD (+41225522104, clinic@aptissen.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evolution of the Oxford Hip Score (OXFORD 12) (time frame: 6 months (M6)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Dec 2025.